This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	DEP domain containing 6 (DEPDC6; DEPTOR); mammalian target of rapamycin (mTOR; FRAP; RAFT1)	Studies in cell culture suggest that inhibiting DEPTOR in a subset of multiple myeloma cells could be useful for treating the disease. In at least one subset of MM cells, high expression of DEPTOR promoted cell growth and survival, and a decrease in DEPTOR levels led to apoptosis. DEPTOR interacts with mTOR and is normally weakly expressed in most cancers. Next steps could include investigating DEPTOR inhibitors in animal models of MM.	Patent and licensing status unavailable	Peterson, T. <i>et al. Cell</i> ; published online May 14, 2009; doi:10.1016/j.cell.2009.03.046 Contact: David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge, Mass. e-mail: sabatini@wi.mit.edu
SciBX 2(22); doi:10.1038/scibx.2009.905 Published online June 4, 2009				